What is Losartankalium/Hydrochloorthiazide Bluefish?
Losartankalium/Hydrochloorthiazide Bluefish contains a combination of Losartankalium/Hydrochloorthiazide Bluefish. Hydrochlorothiazide (Losartankalium/Hydrochloorthiazide Bluefish) is a thiazide diuretic (water pill) that helps prevent your body from absorbing too much salt, which can cause fluid retention. Losartan (Losartankalium/Hydrochloorthiazide Bluefish) is an angiotensin II receptor antagonist. Losartan (Losartankalium/Hydrochloorthiazide Bluefish) keeps blood vessels from narrowing, which lowers blood pressure and improves blood flow.
Losartankalium/Hydrochloorthiazide Bluefish is used to treat high blood pressure (hypertension). It is also used to lower the risk of stroke in certain people with heart disease.
Losartankalium/Hydrochloorthiazide Bluefish may also be used for purposes not listed in this medication guide.
Losartankalium/Hydrochloorthiazide Bluefish indications
Hypertension
Losartankalium/Hydrochloorthiazide Bluefish® is indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular (CV) events, primarily strokes and myocardial infarction. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including Losartan (Losartankalium/Hydrochloorthiazide Bluefish) and Hydrochlorothiazide (Losartankalium/Hydrochloorthiazide Bluefish).
Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC).
Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly.
Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal.
Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy.
This fixed dose combination is not indicated for initial therapy of hypertension, except when the hypertension is severe enough that the value of achieving prompt blood pressure control exceeds the risk of initiating combination therapy in these patients.
Losartankalium/Hydrochloorthiazide Bluefish may be administered with other antihypertensive agents.
Hypertensive Patients With Left Ventricular Hypertrophy
Losartankalium/Hydrochloorthiazide Bluefish is indicated to reduce the risk of stroke in patients with hypertension and left ventricular hypertrophy, but there is evidence that this benefit does not apply to Black patients.
How should I use Losartankalium/Hydrochloorthiazide Bluefish?
Use Losartankalium/Hydrochloorthiazide Bluefish as directed by your doctor. Check the label on the medicine for exact dosing instructions.
- An extra patient leaflet is available with Losartankalium/Hydrochloorthiazide Bluefish. Talk to your pharmacist if you have questions about this information.
- Take Losartankalium/Hydrochloorthiazide Bluefish by mouth with or without food.
- Drinking extra fluids while you are taking Losartankalium/Hydrochloorthiazide Bluefish is recommended. Check with your doctor for instructions.
- Losartankalium/Hydrochloorthiazide Bluefish may increase the amount of urine or cause you to urinate more often when you first start taking it. To keep this from disturbing your sleep, try to take your dose before 6 pm.
- If you take cholestyramine or colestipol, ask your doctor or pharmacist how to take it with Losartankalium/Hydrochloorthiazide Bluefish.
- Continue to take Losartankalium/Hydrochloorthiazide Bluefish even if you feel well. Do not miss any doses.
- If you miss a dose of Losartankalium/Hydrochloorthiazide Bluefish, take it as soon as possible. If it is almost time for your next dose, skip the missed dose and go back to your regular dosing schedule. Do not take 2 doses at once.
Ask your health care provider any questions you may have about how to use Losartankalium/Hydrochloorthiazide Bluefish.
Uses of Losartankalium/Hydrochloorthiazide Bluefish in details
Use: Labeled Indications
Hypertension: Management of hypertension.
Hypertension with left ventricular hypertrophy: To reduce the risk of stroke in patients with hypertension and left ventricular hypertrophy (LVH). Evidence suggests that this benefit does not apply to black patients.
Losartankalium/Hydrochloorthiazide Bluefish description
Each tablet contains Losartan (Losartankalium/Hydrochloorthiazide Bluefish) potassium 50 or 100 mg and Hydrochlorothiazide (Losartankalium/Hydrochloorthiazide Bluefish) 12.5 mg.
Losartan (Losartankalium/Hydrochloorthiazide Bluefish) Potassium: Losartan (Losartankalium/Hydrochloorthiazide Bluefish) potassium, a nonpeptide molecule, is chemically described as 2-butyl-4-chloro-1-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-1H-imidazole-5-methanol monopotassium salt.
Its empirical formula is C22H22ClKN6O.
Losartan (Losartankalium/Hydrochloorthiazide Bluefish) potassium is a white to off-white free-flowing crystalline powder with a molecular weight of 461.01. It is freely soluble in water, soluble in alcohols, and slightly soluble in common organic solvents eg, acetonitrile and methyl ethyl ketone.
Oxidation of the 5-hydroxymethyl group on the imidazole ring results in the active metabolite of Losartan (Losartankalium/Hydrochloorthiazide Bluefish).
Hydrochlorothiazide (Losartankalium/Hydrochloorthiazide Bluefish): Hydrochlorothiazide (Losartankalium/Hydrochloorthiazide Bluefish) is 6-chloro-3,4-dihydro-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide.
Its empirical formula is C7H8ClN3O4S2.
It is a white, or practically white, crystalline powder with a molecular weight of 297.74, which is slightly soluble in water, but freely soluble in sodium hydroxide solution.
Losartankalium/Hydrochloorthiazide Bluefish dosage
Hypertension
The usual starting dose of Losartankalium/Hydrochloorthiazide Bluefish is 50/12.5 (Losartan (Losartankalium/Hydrochloorthiazide Bluefish) 50 mg/Hydrochlorothiazide (Losartankalium/Hydrochloorthiazide Bluefish) 12.5 mg) once daily. The dosage can be increased after 3 weeks of therapy to a maximum of 100/25 (Losartan (Losartankalium/Hydrochloorthiazide Bluefish) 100 mg/Hydrochlorothiazide (Losartankalium/Hydrochloorthiazide Bluefish) 25 mg) once daily as needed to control blood pressure.
Initiate a patient whose blood pressure is not adequately controlled with Losartan (Losartankalium/Hydrochloorthiazide Bluefish) 50 mg monotherapy with Losartankalium/Hydrochloorthiazide Bluefish 50/12.5 once daily. If blood pressure remains uncontrolled after about 3 weeks of therapy, the dosage may be increased to two tablets of Losartankalium/Hydrochloorthiazide Bluefish 50/12.5 once daily or one tablet of Losartankalium/Hydrochloorthiazide Bluefish 100/25 once daily.
Initiate a patient whose blood pressure is not adequately controlled with Losartan (Losartankalium/Hydrochloorthiazide Bluefish) 100 mg monotherapy with Losartankalium/Hydrochloorthiazide Bluefish 100/12.5 (Losartan (Losartankalium/Hydrochloorthiazide Bluefish) 100 mg/Hydrochlorothiazide (Losartankalium/Hydrochloorthiazide Bluefish) 12.5 mg) once daily. If blood pressure remains uncontrolled after about 3 weeks of therapy, increase the dose to two tablets of Losartankalium/Hydrochloorthiazide Bluefish 50/12.5 once daily or one tablet of Losartankalium/Hydrochloorthiazide Bluefish 100/25 once daily.
Initiate a patient whose blood pressure is inadequately controlled with Hydrochlorothiazide (Losartankalium/Hydrochloorthiazide Bluefish) 25 mg once daily, or is controlled but who experiences hypokalemia with this regimen, on Losartankalium/Hydrochloorthiazide Bluefish 50/12.5 once daily, reducing the dose of Hydrochlorothiazide (Losartankalium/Hydrochloorthiazide Bluefish) without reducing the overall expected antihypertensive response. Evaluate the clinical response to Losartankalium/Hydrochloorthiazide Bluefish 50/12.5 and, if blood pressure remains uncontrolled after about 3 weeks of therapy, increase the dose to two tablets of Losartankalium/Hydrochloorthiazide Bluefish 50/12.5 once daily or one tablet of Losartankalium/Hydrochloorthiazide Bluefish 100/25 once daily.
Hypertensive Patients with Left Ventricular Hypertrophy
In patients whose blood pressure is not adequately controlled on 50 mg Losartan (Losartankalium/Hydrochloorthiazide Bluefish) potassium, initiate treatment with Losartankalium/Hydrochloorthiazide Bluefish 50/12.5. If additional blood pressure reduction is needed, increase the dose to Losartankalium/Hydrochloorthiazide Bluefish 100/12.5, followed by Losartankalium/Hydrochloorthiazide Bluefish 100/25. For further blood pressure reduction add other antihypertensives.
Losartankalium/Hydrochloorthiazide Bluefish interactions
See also:
What other drugs will affect Losartankalium/Hydrochloorthiazide Bluefish?
Agents Increasing Serum Potassium
Coadministration of Losartan (Losartankalium/Hydrochloorthiazide Bluefish) with other drugs that raise serum potassium levels may result in hyperkalemia. Monitor serum potassium in such patients.
Lithium
Increases in serum lithium concentrations and lithium toxicity have been reported with concomitant use of angiotensin II receptor antagonists or thiazide diuretics. Monitor lithium levels in patients receiving Losartankalium/Hydrochloorthiazide Bluefish and lithium.
Non-Steroidal Anti-Inflammatory Agents Including Selective Cyclooxygenase-2 Inhibitors
Losartan (Losartankalium/Hydrochloorthiazide Bluefish) Potassium
In patients who are elderly, volume-depleted (including those on diuretic therapy), or with compromised renal function, coadministration of NSAIDs, including selective COX-2 inhibitors, with angiotensin II receptor antagonists (including Losartan (Losartankalium/Hydrochloorthiazide Bluefish)) may result in deterioration of renal function, including possible acute renal failure. These effects are usually reversible. Monitor renal function periodically in patients receiving Losartan (Losartankalium/Hydrochloorthiazide Bluefish) and NSAID therapy.
The antihypertensive effect of angiotensin II receptor antagonists, including Losartan (Losartankalium/Hydrochloorthiazide Bluefish), may be attenuated by NSAIDs, including selective COX-2 inhibitors.
Hydrochlorothiazide (Losartankalium/Hydrochloorthiazide Bluefish)
The administration of a non-steroidal anti-inflammatory agent including a selective COX-2 inhibitor can reduce the diuretic, natriuretic, and antihypertensive effects of loop, potassium-sparing and thiazide diuretics. Therefore, when Losartankalium/Hydrochloorthiazide Bluefish and non-steroidal anti-inflammatory agents including selective COX-2 inhibitors are used concomitantly, observe closely to determine if the desired effect of the diuretic is obtained.
In patients receiving diuretic therapy, coadministration of NSAIDs with angiotensin receptor blockers, including Losartan (Losartankalium/Hydrochloorthiazide Bluefish), may result in deterioration of renal function, including possible acute renal failure. These effects are usually reversible. Monitor renal function periodically in patients receiving Hydrochlorothiazide (Losartankalium/Hydrochloorthiazide Bluefish), Losartan (Losartankalium/Hydrochloorthiazide Bluefish), and NSAID therapy.
Dual Blockade Of The Renin-Angiotensin System (RAS)
Dual blockade of the RAS with angiotensin receptor blockers, ACE inhibitors, or aliskiren is associated with increased risks of hypotension, syncope, hyperkalemia, and changes in renal function (including acute renal failure) compared to monotherapy.
The Veterans Affairs Nephropathy in Diabetes (VA NEPHRON-D) trial enrolled 1448 patients with type 2 diabetes, elevated urinary-albumin-to-creatinine ratio, and decreased estimated glomerular filtration rate (GFR 30 to 89.9 mL/min), randomized them to lisinopril or placebo on a background of Losartan (Losartankalium/Hydrochloorthiazide Bluefish) therapy and followed them for a median of 2.2 years. Patients receiving the combination of Losartan (Losartankalium/Hydrochloorthiazide Bluefish) and lisinopril did not obtain any additional benefit compared to monotherapy for the combined endpoint of decline in GFR, end-stage renal disease, or death, but experienced an increased incidence of hyperkalemia and acute kidney injury compared with the monotherapy group.
Closely monitor blood pressure, renal function, and electrolytes in patients on Losartankalium/Hydrochloorthiazide Bluefish and other agents that affect the RAS.
Do not coadminister aliskiren with Losartankalium/Hydrochloorthiazide Bluefish in patients with diabetes. Avoid use of aliskiren with Losartankalium/Hydrochloorthiazide Bluefish in patients with renal impairment (GFR < 60 mL/min).
The Use Of Hydrochlorothiazide (Losartankalium/Hydrochloorthiazide Bluefish) With Other Drugs
When administered concurrently, the following drugs may interact with thiazide diuretics :
Antidiabetic drugs (oral agents and insulin) — dosage adjustment of the antidiabetic drug may be required.
Cholestyramine and colestipol resins — Absorption of Hydrochlorothiazide (Losartankalium/Hydrochloorthiazide Bluefish) is impaired in the presence of anionic exchange resins. Single doses of either cholestyramine or colestipol resins bind the Hydrochlorothiazide (Losartankalium/Hydrochloorthiazide Bluefish) and reduce its absorption from the gastrointestinal tract by up to 85 and 43 percent, respectively. Stagger the dosage of Hydrochlorothiazide (Losartankalium/Hydrochloorthiazide Bluefish) and the resin such that Hydrochlorothiazide (Losartankalium/Hydrochloorthiazide Bluefish) is administered at least 4 hours before or 4 to 6 hours after the administration of the resin.
Losartankalium/Hydrochloorthiazide Bluefish side effects
See also:
What are the possible side effects of Losartankalium/Hydrochloorthiazide Bluefish?
Clinical Trials Experience
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
Losartan (Losartankalium/Hydrochloorthiazide Bluefish) potassium-Hydrochlorothiazide (Losartankalium/Hydrochloorthiazide Bluefish) has been evaluated for safety in 858 patients treated for essential hypertension and 3889 patients treated for hypertension and left ventricular hypertrophy. Most adverse reactions have been mild and transient in nature and have not required discontinuation of therapy. In controlled clinical trials, discontinuation of therapy due to clinical adverse events was required in only 2.8% and 2.3% of patients treated with the combination and placebo, respectively.
In these double-blind controlled clinical trials, adverse reactions occurring in greater than 2% of subjects treated with Losartan (Losartankalium/Hydrochloorthiazide Bluefish)-Hydrochlorothiazide (Losartankalium/Hydrochloorthiazide Bluefish) and at a greater rate than placebo were: back pain (2.1% vs 0.6%), dizziness (5.7% vs 2.9%), and upper respiratory infection (6.1% vs 4.6%).
The following additional adverse reactions have been reported in clinical trials with Losartankalium/Hydrochloorthiazide Bluefish and/or the individual components:
Blood and the lymphatic system disorders: Anemia, aplastic anemia, hemolytic anemia, leukopenia, agranulocytosis.
Metabolism and nutrition disorders: Anorexia, hyperglycemia, hyperuricemia, electrolyte imbalance including hyponatremia and hypokalemia.
Psychiatric disorders: Insomnia, restlessness.
Nervous system disorders: Dysgeusia, headache, migraine, paraesthesias.
Eye disorders: Xanthopsia, transient blurred vision.
Cardiac disorders: Palpitation, tachycardia.
Vascular disorders: Dose-related orthostatic effects, necrotizing angiitis (vasculitis, cutaneous vasculitis).
Respiratory, thoracic and mediastinal disorders: Nasal congestion, pharyngitis, sinus disorder, respiratory distress (including pneumonitis and pulmonary edema).
Gastrointestinal disorders: Dyspepsia, abdominal pain, gastric irritation, cramping, diarrhea, constipation, nausea, vomiting, pancreatitis, sialoadenitis.
Hepato-biliary disorders: Jaundice (intrahepatic cholestatic jaundice).
Skin and subcutaneous tissue disorders: Rash, pruritus, purpura, toxic epidermal necrolysis, urticaria, photosensitivity, cutaneous lupus erythematosus.
Musculoskeletal and connective tissue disorders: Muscle cramps, muscle spasm, myalgia, arthralgia.
Renal and urinary disorders: Glycosuria, renal dysfunction, interstitial nephritis, renal failure.
Reproductive system and breast disorders: Erectile dysfunction/impotence.
General disorders and administration site conditions: Chest pain, edema/swelling, malaise, fever, weakness.
Investigations: Liver function abnormalities.
Cough
Persistent dry cough has been associated with ACE-inhibitor use and in practice can be a cause of discontinuation of ACE-inhibitor therapy. Two prospective, parallel-group, double-blind, randomized, controlled trials were conducted to assess the effects of Losartan (Losartankalium/Hydrochloorthiazide Bluefish) on the incidence of cough in hypertensive patients who had experienced cough while receiving ACE-inhibitor therapy. Patients who had typical ACE-inhibitor cough when challenged with lisinopril, whose cough disappeared on placebo, were randomized to Losartan (Losartankalium/Hydrochloorthiazide Bluefish) 50 mg, lisinopril 20 mg, or either placebo (one study, n=97) or 25 mg Hydrochlorothiazide (Losartankalium/Hydrochloorthiazide Bluefish) (n=135). The double-blind treatment period lasted up to 8 weeks. The incidence of cough is shown in Table 1 below.
| |||
| Study 1* | HCTZ | Losartan (Losartankalium/Hydrochloorthiazide Bluefish) | Lisinopril |
| Cough | 25% | 17% | 69% |
| Study 2† | Placebo | Losartan (Losartankalium/Hydrochloorthiazide Bluefish) | Lisinopril |
| Cough | 35% | 29% | 62% |
These studies demonstrate that the incidence of cough associated with Losartan (Losartankalium/Hydrochloorthiazide Bluefish) therapy, in a population that all had cough associated with ACE-inhibitor therapy, is similar to that associated with Hydrochlorothiazide (Losartankalium/Hydrochloorthiazide Bluefish) or placebo therapy.
Cases of cough, including positive re-challenges, have been reported with the use of Losartan (Losartankalium/Hydrochloorthiazide Bluefish) in postmarketing experience.
Postmarketing Experience
The following adverse reactions have been identified during post-approval use of Losartankalium/Hydrochloorthiazide Bluefish. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to estimate their frequency reliably or to establish a causal relationship to drug exposure.
Digestive: Hepatitis has been reported rarely in patients treated with Losartan (Losartankalium/Hydrochloorthiazide Bluefish).
Hematologic: Thrombocytopenia.
Hypersensitivity: Angioedema, including swelling of the larynx and glottis, causing airway obstruction and/or swelling of the face, lips, pharynx, and/or tongue has been reported rarely in patients treated with Losartan (Losartankalium/Hydrochloorthiazide Bluefish); some of these patients previously experienced angioedema with other drugs including ACE inhibitors. Vasculitis, including Henoch-Schönlein purpura, has been reported with Losartan (Losartankalium/Hydrochloorthiazide Bluefish). Anaphylactic reactions have been reported.
Musculoskeletal: rhabdomyolysis
Skin: Erythroderma
Losartankalium/Hydrochloorthiazide Bluefish contraindications
Hypersensitivity to Losartan (Losartankalium/Hydrochloorthiazide Bluefish), sulphonamide-derived substances (as Hydrochlorothiazide (Losartankalium/Hydrochloorthiazide Bluefish)) or to any of the excipients of Losartankalium/Hydrochloorthiazide Bluefish.
Therapy resistant hypokalemia or hypercalcemia; severe hepatic impairment; cholestasis and biliary obstructive disorders; refractory hyponatremia; symptomatic hyperuricemia/gout; 2nd and 3rd trimester of pregnancy; lactation; severe renal impairment (ie, creatinine clearance <30 mL/min); anuria.
Excipient: Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take Losartankalium/Hydrochloorthiazide Bluefish.
Use in lactation: It is not known whether Losartan (Losartankalium/Hydrochloorthiazide Bluefish) is excreted in human milk. However, Losartan (Losartankalium/Hydrochloorthiazide Bluefish) is excreted in the milk of lactating rats. Because no information is available regarding the use of Losartan (Losartankalium/Hydrochloorthiazide Bluefish) during breastfeeding, Losartan (Losartankalium/Hydrochloorthiazide Bluefish) is not recommended and alternative treatments with better established safety profiles during breastfeeding are preferable, especially while nursing a newborn or preterm infant.
Thiazides pass into human milk and may inhibit lactation. Because of the potential for adverse effects on the nursing infant, Losartan (Losartankalium/Hydrochloorthiazide Bluefish)/HCTZ is contraindicated during breastfeeding.
Active ingredient matches for Losartankalium/Hydrochloorthiazide Bluefish:
Hydrochlorothiazide/Losartan in Netherlands.
List of Losartankalium/Hydrochloorthiazide Bluefish substitutes (brand and generic names) | Sort by popularity |
| Unit description / dosage (Manufacturer) | Price, USD |
| Losartankalium/Hydrochloorthiazide Mylan (Netherlands) | |
| Losartankalium/hydrochlorthiazid Actavis (Denmark) | |
| Losartankalium/hydrochlorthiazid Amneal (Denmark) | |
| Losartankalium/hydrochlorthiazid Krka (Denmark) | |
| Losartankalium/Hydrochlorthiazid Medical Valley (Denmark) | |
| Losartankalium/hydrochlorthiazid Teva (Denmark) | |
| Losartar-H (India) | |
| Losartar-H Losartan K , Hydrochlorothiazide TAB / 10 (Shrrishti HC) | $ 0.60 |
| 10's (Shrrishti HC) | $ 0.60 |
| LOSARTAR-H tab 10's (Shrrishti HC) | $ 0.60 |
| Losartas HT (Peru) | |
| Losartas HT Hydrochlorothiazide 12.5mg, Losartan K 50mg TAB / 7 | $ 0.69 |
| Losartas HT Tablet (Intas Pharmaceuticals Ltd) | $ 0.11 |
| Losarteg HCT (El Salvador) | |
| Losartic HC (Slovenia) | |
| Losartic Plus (Croatia (Hrvatska), Serbia) | |
| Losartil-Plus (Turkey) | |
| Losasis-H | |
| Losasis-H 50mg/12.5mg Tablet (CHS Formulations) | $ 0.08 |
| Losastal-H Tablet | |
| Losastal-H Tablet (Stallion Laboratories Pvt Ltd) | $ 0.08 |
| LOSASUN HT | |
| LOSASUN HT TABLET 1 strip / 10 tablets each (Sunij Pharma Pvt Ltd) | $ 0.35 |
| LOSATAN H | |
| LOSATAN H TABLET 1 strip / 10 tablets each (Biochem Pharmaceutical Industries) | $ 0.60 |
| Losatan Hz (Bangladesh) | |
| LOSATEC H | |
| LOSATEC H 50 MG/12.5 MG TABLET 1 strip / 10 tablets each (RPG Life Sciences Ltd) | $ 1.00 |
| Losatec-H (India) | |
| Losatec-H Capsule/ Tablet / 12.5mg-50mg / 10 units (RPG LS) | $ 0.64 |
| Losatec-H Losartan K 50mg, Hydrochlorothiazide 12.5mg TAB / 10 (RPG LS) | $ 0.83 |
| 10's (RPG LS) | $ 0.83 |
| LOSATEC-H tab 10's (RPG LS) | $ 0.83 |
| Losatrix Comp (Finland, Sweden) | |
| LOSATRUST H | |
| LOSATRUST H TABLET 1 strip / 10 tablets each (Centaur Pharmaceuticals Pvt Ltd) | $ 0.76 |
| Losatrust-H (India) | |
| Losatrust-H Capsule/ Tablet / 12.5mg-50mg / 10 units (Centaur (Sankalp)) | $ 0.43 |
| Losatrust-H Losartan 50mg, Hydrochlorothiazide 12.5mg TAB / 10 (Centaur (Sankalp)) | $ 0.47 |
| 10's (Centaur (Sankalp)) | $ 0.52 |
| Losatrust-H Losartan 50mg, Hydrochlorothiazide 12.5mg FC-TAB / 10 (Centaur (Sankalp)) | $ 0.52 |
| LOSATRUST-H film-coated tab 10's (Centaur (Sankalp)) | $ 0.52 |
| LOSAVAS H | |
| LOSAVAS H TABLET 1 strip / 10 tablets each (Orchid Chemicals & Pharmaceuticals Ltd) | $ 0.88 |
| Losavik -H | |
| Losavik -H Losartan K 50mg, Hydrochlorothiazide 12.5mg TAB / 100 | $ 6.63 |
| Losavik-H (India) | |
| 100's (Anvik Biotech) | $ 6.63 |
| Losavik-H Losartan K 50mg, Hydrochlorothiazide 12.5mg TAB / 100 (Anvik Biotech) | $ 6.63 |
| LOSAVIK-H tab 10's (Anvik Biotech) | $ 0.54 |
| Losazid (Italy) | |
| Losazid Orifarm (Denmark) | |
| Losazid Paranova (Denmark) | |
| Losazide (Greece) | |
| Loscar Plus (Colombia) | |
See 1294 substitutes for Losartankalium/Hydrochloorthiazide Bluefish | |
References
- DailyMed. "AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; OLMESARTAN MEDOXOMIL: DailyMed provides trustworthy information about marketed drugs in the United States. DailyMed is the official provider of FDA label information (package inserts).". https://dailymed.nlm.nih.gov/dailyme... (accessed September 17, 2018).
- DailyMed. "LOSARTAN POTASSIUM: DailyMed provides trustworthy information about marketed drugs in the United States. DailyMed is the official provider of FDA label information (package inserts).". https://dailymed.nlm.nih.gov/dailyme... (accessed September 17, 2018).
- PubChem. "losartan". https://pubchem.ncbi.nlm.nih.gov/com... (accessed September 17, 2018).
Reviews
The results of a survey conducted on ndrugs.com for Losartankalium/Hydrochloorthiazide Bluefish are given in detail below. The results of the survey conducted are based on the impressions and views of the website users and consumers taking Losartankalium/Hydrochloorthiazide Bluefish. We implore you to kindly base your medical condition or therapeutic choices on the result or test conducted by a physician or licensed medical practitioners.User reports
Consumer reported useful
No survey data has been collected yetConsumer reported price estimates
No survey data has been collected yetConsumer reported time for results
No survey data has been collected yetConsumer reported age
No survey data has been collected yetConsumer reviews
There are no reviews yet. Be the first to write one! |
Information checked by Dr. Sachin Kumar, MD Pharmacology
